UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~the~~

the Securities Exchange Act of 1934

Date of ~~Report~~report (~~Date~~date of earliest event reported): – August 519, 2010

US Oncology Holdings, Inc.

US Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware Delaware		333-~~126922~~144492 0-26190		20-0873619 84-1213501
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

10101 Woodloch Forest

The Woodlands, Texas 77380

(Address of principal executive offices including zip code)

(281) 863-1000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 25.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition.~~Officers; Appointment of Certain Officers

(b) On August 5 19, 2010, USMichael ~~Oncology, Inc~~A. Sicuro, ~~issued~~Chief aFinancial ~~press~~Officer ~~release~~of ~~regarding~~each ~~earnings~~of ~~for~~US ~~the~~Oncology ~~second~~and ~~quarter ended June 30, 2010 for~~ US Oncology Holdings, Inc. ~~and~~(the ~~its~~“Companies”), ~~wholly~~informed ~~owned~~the ~~subsidiary~~Companies USof ~~Oncology~~his intent to resign as Chief Financial Officer, ~~Inc~~effective August 27, 2010. AMr. ~~copy~~Sicuro will remain an employee of the ~~press~~Companies ~~release~~through isDecember ~~furnished~~31, ~~herewith~~2010, assubject ~~Exhibit~~to 99extension.1.

~~The information~~(c) inEffective ~~this~~upon ~~report~~Mr. ~~and~~Sicuro’s ~~the~~resignation, ~~attached~~David ~~exhibit are provided under Item 2~~W.02 ~~of Form 8-K and are furnished to the Securities and Exchange Commission (“SEC”)~~Young, ~~but~~who ~~shall~~currently beserves ~~not~~as ~~deemed “filed” with~~ the ~~SEC~~Senior ~~for~~Vice ~~purposes~~President of ~~Section 18~~ ofUS ~~the~~Oncology’s ~~Securities~~BioPharmaceutical ~~Exchange~~Solutions ~~Act of 1934~~Group, ashas ~~amended,~~been orappointed ~~otherwise~~to ~~subject~~serve toas ~~the~~Interim ~~liabilities~~Chief ofFinancial ~~that~~Officer. ~~section~~Mr. orYoung ofhas ~~Sections~~been 11with ~~and~~US ~~12(a)(2)~~Oncology ofin ~~the~~various ~~Securities~~operational ~~Act~~and offinance ~~1933,~~positions assince ~~amended~~2005. ~~The~~Prior ~~information~~to injoining ~~this~~US ~~report~~Oncology, ~~and~~he ~~the~~served ~~attached exhibit~~as ~~shall~~Senior ~~not~~Vice bePresident ~~incorporated by reference into any filing~~ of ~~the~~Finance ~~registrant,~~at ~~whether~~Coach ~~made~~USA ~~before~~and oras ~~after~~a ~~the~~Senior ~~date~~Manager ~~hereof,~~at ~~regardless~~Arthur ofAndersen. ~~any~~Mr. ~~general~~Young ~~incorporation~~is ~~language~~a inCertified ~~such~~Public ~~filing~~Accountant.

~~ITEM~~(e) 9In connection with his resignation as CFO, including in respect of any period during which he remains an employee of the Companies after August 27, 2010, Mr.01 ~~Financial~~Sicuro ~~Statements~~will ~~and~~receive ~~Exhibits~~a total of approximately $581,966 in cash from the Company, payable over a period of 13 months based upon (1) a prorated bonus for the period from January 1, 2010 through August 27, 2010, plus (2) an amount equal to Mr. Sicuro’s base salary for 13 months. In addition, Mr. Sicuro will be eligible to receive an additional bonus amount of up to $154,050 during 2011, based on bonuses paid to employees of the Companies generally. In addition, through September 27, 2011, Mr. Sicuro will be able to continue to participate in the Company’s health plans on terms similar to those offered to current employees of the Company

~~The following~~SIGNATURE ~~exhibit is furnished as part of this Current Report on Form 8-K:~~

Exhibit 99.1 Press Release of US Oncology, Inc. dated August 5, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 10, 2010	By:	/s/ KEVIN F. KRENZKE
		Kevin F. Krenzke
		Chief Accounting Officer

Dated: August 24, 2010


US ONCOLOGY HOLDINGS, INC. US ONCOLOGY, INC.

By:		Kevin F. Krenzke
Name:		Kevin F. Krenzke
Title:		Chief Accounting Officer

Filing Compare · US ONCOLOGY INC